International Journal of Respiratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us 443308081224

EFFECTS OF THE ANTI-CANCER PREPARATION NSC-631570 (UKRAINE) ON LUNG CANCER

5th International Congress on Lung Cancer and Copd
June 25-26, 2018 | Amsterdam, Netherlands

Wassil Nowicky

Nowicky Pharma, Austria

Scientific Tracks Abstracts : Int J Respir Med

Abstract:

Clinical efficacy of NSC‐631570 is not coincidental or even ‘spontaneous remission’ but rather a consequence of its mechanisms of action confirmed in various in vitro and in vivo studies. NSC‐631570 has been tested on more than 100 cancer cell lines so far. Among others, NSC‐631570 was tested at the National Cancer Institute (Bethesda, Maryland, USA) on 60 cell lines representing eight important human malignant tumors: brain tumors, ovarian, small cell and non‐small lung cancer, colon cancer, kidney cancer, leukaemia and malignant melanoma. NSC‐631570 exerted toxic effects against all these cell lines. Compared to 5‐fluorouracil (5‐FU) and gemcitabine, two standard cytotoxic agents in the treatment of digestive tract tumors, NSC‐631570 achieved better results and not only inhibited the cell growth but reduced the cell mass, also. In 1998, a group around Anne Panzer (University of Pretoria, South Africa) proved the selective effect of NSC‐631570 on molecular level. Tests on human cervical carcinoma cells HeLa, squamous cell carcinoma WHCO5 and normal equine lung cell lines demonstrated that NSC‐631570 is selectively toxic against cancer cells. It causes a metaphase block which is characterized by an abnormal distribution of chromosomes and the formation of micronuclei and results in apoptosis. Normal cells are not influenced in the process. NSC‐631570 was effective in the therapy of recurring lung diseases in children from the Chernobyl area.

Biography:

Wassil Nowicky is the President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study as the Radio Technical Faculty in the Technical University of Lviv (Ukrainee) in the end of 1955. He was the author of over 300 scientific articles dedicated to cancer research. He is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress. He has received the award for merits of National Guild of Pharmacists of America, the award of Austrian Society of Sanitary, Hygiene and Public Health Services and others.

Email:[email protected]

PDF HTML